OncoPep is dedicated to developing transformative targeted immunotherapeutics to prevent the progression of cancer, maintain quality of life among patients and potentially prolong survival.


Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine, OncoPep’s proprietary technology is designed to be used on its own or in combination with other immunotherapeutics.

Our core technology is founded on targeting multiple tumor associated antigens using a multi-peptide approach to cancer vaccines based on research conducted in the labs of Kenneth Anderson, M.D., and Nikhil Munshi, M.D., world renowned clinical investigators in the treatment of hematologic oncology, at the Dana Farber Cancer Institute (Boston, MA, USA).

Our initial focus is on smoldering multiple myeloma (SMM), an area of unmet medical need for which the current treatment regimen is “active monitoring”. SMM is an asymptomatic precursor to multiple myeloma (MM). A cancer of the plasma cells, MM is the second most common blood cancer with an estimated 30,000 patients newly diagnosed in 2017 1. This is a painful disease for which there is still no cure. Working with the patient's immune system at this earlier stage of their cancer has the potential to alter the rate of cancer progression to MM in patients diagnosed with SMM.

OncoPep’s lead program, PVX-410, is a multi-peptide investigational cancer vaccine in development for SMM and triple negative breast cancer (TNBC). PVX-410 is being investigated to stop the progression of the disease from SMM to MM. The vaccine has been evaluated in a Phase 1 study as a stand-alone therapy and in combination with lenalidomide, an immunomodulatory drug. PVX-410 was granted orphan drug designation for use in treating MM from the U.S. Food and Drug Administration in 2013.

1 Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda,




Doris is the Chief Executive Officer and Co-founder of OncoPep, Inc. Doris has served in a variety of leadership roles for biopharmaceutical and healthcare companies including Genzyme (now Sanofi Genzyme). Most recently, Doris was Chief Executive Officer at Healagenics, a health-care technology firm focused on the wound-care market, and Vice President of Market Development at Antigenics (now Agenus), a cancer vaccine development company. Doris received her Bachelor of Science from Virginia Polytechnic Institute and State University and her Master of Business Administration from Boston University.


Marc A. Cohen is a co-founder and the Executive Chairman of OncoPep. He is also a Co-founder and Executive Chairman of C4 Therapeutics, Chairman of Frequency Therapeutics and Regenacy Pharmaceuticals. Additionally, Marc is the Co-founder and Chief Executive Officer of Bublup, Inc. and COBRO Ventures, Inc. He was the Chief Executive Officer, Chairman and Co-founder of OPNET Technologies, Inc., a world leader in network and application performance management. OPNET was sold to Riverbed Technology in December 2012. He is currently a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients. Marc received his undergraduate degree in Engineering Science from Harvard University and an M.S. in Electrical Engineering from Stanford University.

Joslyn Dobson is an institutional investment manager and private investor who founded and sold Palladium Capital Management after managing assets for Criterion Asset Management in Houston and Boston. She is currently the managing Partner of JDSD Investments LTD, with interests in Texas and New York. In addition to being a member of the Presidential Visiting Committee at the Dana Farber Cancer Institute, Joslyn is a co-founder and on the Board of Directors for OncoPep. Joslyn is a board member and co-founder of CapCityKids - helping homeless children in Austin succeed in school. She is on the Board of Advisors to the University of Texas at Austin School of Social Work, as well as a member of the UT Presidential Development Board.

Ken is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. His research and impact on patient outcomes has been widely recognized including election to the National Institute of Medicine and the Royal Colleges of Physicians and Pathologists and the 2012 American Cancer Society Medal of Honor. His research has pioneered understanding of the tumor microenvironment in multiple myeloma and he has played an extensive role in the development and approval of numerous new treatments for myeloma patients. He also serves on the Board of Directors for C4 Therapeutics. He received his MD from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. He is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society.

Nikhil C. Munshi, MD is Professor of Medicine at the Harvard Medical School and the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Myeloma Center at the Dana Farber Cancer Institute. He is an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare system, Harvard Medical School. Dr. Munshi received his medical degree from the S.S.G. Hospital and M.S. University in Baroda, India. He completed a Research Fellowship in Medical Oncology at the Johns Hopkins Oncology Center in Baltimore, Maryland, before receiving a clinical fellowship in hematology/oncology at Indiana University Medical Center. Dr. Munshi joined the staff at the Myeloma Center at the University of Arkansas in 1992 in research and clinical roles and was promoted to Professor of Medicine and Director of the Clinical Gene Transduction Laboratory at the Arkansas Cancer Research Center in July 2000. He has over 350 peer-reviewed publications and book chapters. In 2013, he was awarded the most prestigious award in myeloma, the “Waldenstrom’s Award” for Most Distinguished Lifetime Achievement in Myeloma Research.

Dr. Elena Prokupets co-founded Lenel Systems International and was President, CEO and Chairman of the Board until its sale to United Technology Corporation (UTC). Elena also co-founded and led Edicon Systems, a pioneer in electronic images and electronic photography, that is now owned by Kodak. Dr. Prokupets was on the Board of Directors of Acetylon Pharmaceuticals until it was sold to Celgene and currently serves on the Board of Directors for Regenacy Pharmaceuticals and C4 Therapeutics. She is also a Trustee of the University of Rochester and the Managing Director of the Metropolitan Opera of New York. Elena has an MS in Electrical Engineering and PhD in Computer Science.

Bruce is a Partner at NewSpring Capital. Bruce was the Chairman and Chief Executive Officer at Barr Pharmaceuticals Inc. from 1994 to 2008. Prior to Barr, he was a Partner at Winston & Strawn LLP and Bishop, Cook, Purcell, and Reynolds. Bruce has been on the Board of Directors for Cardinal Health and Momenta Pharmaceuticals since 2009. He is also on the Board of Directors for C4 Therapeutics and Abon Pharmaceuticals. Bruce was the Chairman of Generic Pharmaceutical Association from 2006 to 2007. Mr. Downey received a BS degree from Miami University and a JD from Ohio State University.

Jay is a co-founder and principal of EG Capital Group. Previously, Jay was a member of mergers and acquisitions teams at JP Morgan in New York and London. Jay also chairs the Advisory Board at the Naomi Berrie Diabetes Center at Columbia University Medical Center and is on the board of C4 Therapeutics.